EXCLUSIVE: Vivani Medical Tells Benzinga 'Clinical Development of Vivani's Exenatide Implant in Overweight and Obese Patients as Part of the Company's NPM-115 Program Remains on Track to Commence in the Fourth Quarter of 2024'
EXCLUSIVE: Vivani Medical Tells Benzinga 'Clinical Development of Vivani's Exenatide Implant in Overweight and Obese Patients as Part of the Company's NPM-115 Program Remains on Track to Commence in the Fourth Quarter of 2024'
獨家報道：Vivani醫療告訴彭卓 'Vivani關於超重和肥胖患者的埃塞那肽植入物的臨床開發作爲公司NPm-115計劃的一部分，仍計劃於2024年第四季度啓動。'
EXCLUSIVE: Vivani Medical Tells Benzinga 'Clinical Development of Vivani's Exenatide Implant in Overweight and Obese Patients as Part of the Company's NPM-115 Program Remains on Track to Commence in the Fourth Quarter of 2024'
獨家報道：Vivani醫療告訴彭卓 'Vivani關於超重和肥胖患者的埃塞那肽植入物的臨床開發作爲公司NPm-115計劃的一部分，仍計劃於2024年第四季度啓動。'
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間